Literature DB >> 22728753

Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.

Andrea De Luca, Katleen de Gaetano Donati, Alessandro Cozzi-Lepri, Manuela Colafigli, Amalia De Curtis, Maria Rosaria Capobianchi, Andrea Antinori, Andrea Giacometti, Giacomo Magnani, Vincenzo Vullo, Roberto Cauda, Licia Iacoviello, Antonella d'Arminio Monforte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22728753     DOI： 10.1097/QAI.0b013e318259875b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  5 in total

1.  Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected men.

Authors:  Jordan E Lake; Quynh T Vo; Lisa P Jacobson; Ned Sacktor; Eric N Miller; Wendy S Post; James T Becker; Frank J Palella; Ann Ragin; Eileen Martin; Cynthia A Munro; Todd T Brown
Journal:  Antivir Ther       Date:  2015-03-26

2.  Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.

Authors:  Kunchok Dorjee; Tsering Choden; Sanjiv M Baxi; Craig Steinmaus; Arthur L Reingold
Journal:  Int J Antimicrob Agents       Date:  2018-07-21       Impact factor: 5.283

3.  Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Authors:  Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren
Journal:  BMC Med       Date:  2016-03-31       Impact factor: 8.775

4.  Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.

Authors:  Maria Concetta Postorino; Eugenia Quiros-Roldan; Franco Maggiolo; Simona Di Giambenedetto; Nicoletta Ladisa; Giuseppe Lapadula; Silvia Lorenzotti; Laura Sighinolfi; Filippo Castelnuovo; Massimo Di Pietro; Daria Gotti; Nicola Mazzini; Carlo Torti
Journal:  Open AIDS J       Date:  2016-07-15

5.  Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.

Authors:  Kunchok Dorjee; Sanjiv M Baxi; Arthur L Reingold; Alan Hubbard
Journal:  BMC Infect Dis       Date:  2017-10-27       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.